Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Cash & Equivalents: 2020-2023

Historic Cash & Equivalents for Immuneering (IMRX) over the last 4 years, with Dec 2023 value amounting to $59.4 million.

  • Immuneering's Cash & Equivalents fell 33.56% to $45.2 million in Q3 2024 from the same period last year, while for Sep 2024 it was $45.2 million, marking a year-over-year decrease of 33.56%. This contributed to the annual value of $59.4 million for FY2023, which is 18.22% down from last year.
  • Immuneering's Cash & Equivalents amounted to $59.4 million in FY2023, which was down 18.22% from $72.6 million recorded in FY2022.
  • Immuneering's Cash & Equivalents' 5-year high stood at $74.9 million during FY2021, with a 5-year trough of $37.1 million in FY2020.
  • In the last 3 years, Immuneering's Cash & Equivalents had a median value of $72.6 million in 2022 and averaged $69.0 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first soared by 101.91% in 2021, then declined by 18.22% in 2023.
  • Immuneering's Cash & Equivalents (Yearly) stood at $37.1 million in 2020, then surged by 101.91% to $74.9 million in 2021, then decreased by 3.01% to $72.6 million in 2022, then fell by 18.22% to $59.4 million in 2023.